Jerry Karabelas

Track

Insider profile

Currently holds positions in Polyphor AG, Human Genome Sciences Inc and Bausch Health Companies Inc

Performance

Overall performance
1.6
Performance over holding periods
1.6
30 days 90 days 120 days
Average return -3% 8.2% 15.1%
Success rate 3% 68% 82%
Transactions
2 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chairman of the Board Polyphor AG None -
Chairman of the Board, Presiding Independent Director Human Genome Sciences Inc Oct. 17, 2004 -
Independent Director Bausch Health Companies Inc June 1, 2016 -
Chairman of the Board Polyphor AG None -
Independent Director Rocket Pharmaceuticals Inc July 1, 2012 - June 23, 2016
Independent Director Vanda Pharmaceuticals Inc Dec. 16, 2010 - Jan. 18, 2012
Jerry Karabelas's trades of Regenxbio Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
460.57
Quantity 26,342 +22.9%
Value US$3,771,416
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
164.63
Quantity 23,945 -17.7%
Value US$4,538,913
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
318.18
Quantity 83,648 -36.3%
Value US$2,900,097
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
15.00
Quantity 100 -0.9%
Value US$1,500
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
14.59
Quantity 400 -3.4%
Value US$5,834
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
13.45
Quantity 9,600 -44.9%
Value US$129,120
US Regenxbio Inc (RGNX)
Transaction date
Proposed sale
Price
14.25
Quantity 31,000
Value US$441,750
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
15.05
Quantity 11,000 -49.4%
Value US$165,495
US Regenxbio Inc (RGNX)
Transaction date
Planned sale
Price
11.27
Quantity 10,000 -47.0%
Value US$112,691
US Regenxbio Inc (RGNX)
Transaction date
Proposed sale
Price
11.70
Quantity 30,000
Value US$351,000
Transaction date
Purchase
Price
24.65
Quantity 4,000 +23.9%
Value US$98,600
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-02 2024-10-01
US Regenxbio Inc (RGNX)
PlS Planned sale
26,342 +22.9%
460.57
US$3,771,416 		26,342 +22.9% 460.57 US$3,771,416
2024-09-04 2024-09-03
US Regenxbio Inc (RGNX)
PlS Planned sale
23,945 -17.7%
164.63
US$4,538,913 		23,945 -17.7% 164.63 US$4,538,913
2024-09-04 2024-09-03
US Regenxbio Inc (RGNX)
PlS Planned sale
83,648 -36.3%
318.18
US$2,900,097 		83,648 -36.3% 318.18 US$2,900,097
2024-08-05 2024-08-01
US Regenxbio Inc (RGNX)
PlS Planned sale
100 -0.9%
15.00
US$1,500 		100 -0.9% 15.00 US$1,500
2024-08-05 2024-08-01
US Regenxbio Inc (RGNX)
PlS Planned sale
400 -3.4%
14.59
US$5,834 		400 -3.4% 14.59 US$5,834
2024-08-05 2024-08-01
US Regenxbio Inc (RGNX)
PlS Planned sale
9,600 -44.9%
13.45
US$129,120 		9,600 -44.9% 13.45 US$129,120
2024-08-01 2024-08-01
US Regenxbio Inc (RGNX)
PrS Proposed sale
31,000
14.25
US$441,750 		31,000 14.25 US$441,750
2024-07-30 2024-07-29
US Regenxbio Inc (RGNX)
PlS Planned sale
11,000 -49.4%
15.05
US$165,495 		11,000 -49.4% 15.05 US$165,495
2024-07-03 2024-07-01
US Regenxbio Inc (RGNX)
PlS Planned sale
10,000 -47.0%
11.27
US$112,691 		10,000 -47.0% 11.27 US$112,691
2024-07-01 2024-07-01
US Regenxbio Inc (RGNX)
PrS Proposed sale
30,000
11.70
US$351,000 		30,000 11.70 US$351,000
2016-08-12 2016-08-11
B Purchase
4,000 +23.9%
24.65
US$98,600 		4,000 +23.9% 24.65 US$98,600
2015-02-25 2015-02-23
B Purchase
603,832 +36.1%
6.00
US$3,622,992 		603,832 +36.1% 6.00 US$3,622,992